Immuneering (IMRX) Income from Continuing Operations (2020 - 2023)
Historic Income from Continuing Operations for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.5 million.
- Immuneering's Income from Continuing Operations fell 1543.57% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 803.36%. This contributed to the annual value of -$54.8 million for FY2023, which is 849.74% down from last year.
- Immuneering's Income from Continuing Operations amounted to -$15.5 million in Q4 2023, which was down 1543.57% from -$13.1 million recorded in Q3 2023.
- Immuneering's Income from Continuing Operations' 5-year high stood at -$3.6 million during Q2 2020, with a 5-year trough of -$15.5 million in Q4 2023.
- Moreover, its 4-year median value for Income from Continuing Operations was -$11.5 million (2022), whereas its average is -$10.2 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 12162.34% in 2021, then plummeted by 81.48% in 2023.
- Over the past 4 years, Immuneering's Income from Continuing Operations (Quarter) stood at -$5.8 million in 2020, then tumbled by 88.02% to -$11.0 million in 2021, then dropped by 22.75% to -$13.5 million in 2022, then fell by 15.44% to -$15.5 million in 2023.
- Its Income from Continuing Operations stands at -$15.5 million for Q4 2023, versus -$13.1 million for Q3 2023 and -$12.3 million for Q2 2023.